Avista Healthcare Partners Announces Promotions
Rhea-AI Summary
Avista Healthcare Partners (ORGO) announced on January 5, 2026 three promotions within its investment team: Ryan Moran and Garrett Lustig were promoted to Partner, and Elaine Tang was promoted to Principal.
The announcement highlights each executive's tenure and background: Moran joined Avista in 2018 with prior roles at Morgan Stanley Capital Partners and Bank of America Merrill Lynch; Lustig joined in 2015 from Centerview Partners; Tang joined in 2022 from Partners Group. Each exec currently serves on multiple portfolio company boards, including Organogenesis (Nasdaq: ORGO) for Lustig.
David Burgstahler, CEO, said the promotions reflect Avista's growth and focus on developing leadership as the firm pursues healthcare investment opportunities.
Positive
- None.
Negative
- None.
News Market Reaction 10 Alerts
On the day this news was published, ORGO declined 4.85%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.5% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $29M from the company's valuation, bringing the market cap to $560M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ORGO was down 10.52% while peers showed mixed moves: SIGA +1.62%, EOLS +0.15%, AQST -1.38%, AKBA -4.91%, ESPR -3.89%. This points to stock-specific pressure rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Regulatory filing update | Positive | +2.1% | Rolling BLA submission for ReNu with final modules expected in 1H 2026. |
| Dec 15 | Regulatory meeting news | Positive | +0.2% | Successful FDA Type-B meeting and plan to initiate rolling BLA for ReNu. |
| Nov 06 | Earnings and guidance | Positive | -2.0% | Record Q3 revenue, higher profitability, and raised FY2025 revenue and EBITDA guidance. |
| Nov 03 | Reimbursement policy news | Positive | -5.9% | CMS finalized skin substitute payment reform viewed as supportive for PMA products. |
| Oct 31 | Equity compensation grants | Neutral | -5.9% | Inducement stock options and RSUs granted to new CTO under Nasdaq Rule 5635(c)(4). |
Recent history shows several positive fundamental or regulatory updates, yet price reactions were often muted or negative, suggesting a tendency for selling or profit-taking even on constructive news.
Over the past few months, ORGO reported multiple milestones. On Nov 6, 2025, it delivered record Q3 revenue and raised 2025 guidance, yet shares fell. Regulatory and policy-related news on CMS payment reform and inducement equity grants around late October–November 2025 also coincided with declines. In contrast, BLA-related updates for ReNu on Dec 15 and Dec 23, 2025 produced modest gains. Against this backdrop, today’s board-related news about an Avista partner is comparatively routine versus prior clinical and financial catalysts.
Market Pulse Summary
This announcement highlights leadership depth at Avista, one of ORGO’s key stakeholders, with Avista executives continuing to serve on Organogenesis’s Board. In the past six months ORGO has advanced a BLA for ReNu, reported record Q3 revenue, and navigated reimbursement and governance developments. Investors may watch for future updates on ReNu’s regulatory path, Medicare coverage changes effective January 1, 2026, and any further Board or ownership disclosures.
AI-generated analysis. Not financial advice.
- Ryan Moran has been promoted to Partner;
- Garrett Lustig has been promoted to Partner; and
- Elaine Tang has been promoted to Principal.
David Burgstahler, Managing Partner and Chief Executive Officer of Avista, commented:
"We are thrilled to recognize Ryan, Garrett, and Elaine for their outstanding contributions to Avista's success as well as their partnerships with our portfolio company management teams and Boards. The firm's growth and continued development of our team underscore the depth and strength of the firm's leadership team. We look forward to their leadership as we pursue new and compelling investment opportunities in the healthcare sector."
Ryan Moran: Ryan joined Avista in 2018. Prior to joining Avista, he was an Associate at Morgan Stanley Capital Partners where he focused on private equity investments across a range of industries. Prior to joining Morgan Stanley, he worked as an Analyst in the investment banking division at Bank of America Merrill Lynch. Ryan received a B.A. from The George Washington University and an M.B.A. from Harvard Business School. He currently serves as a Director of Cosette Pharmaceuticals, GCM Holding Corporation, WellSpring Consumer Healthcare, and XIFIN.
Garrett Lustig: Garrett joined Avista in 2015. Prior to joining Avista, he worked in investment banking at Centerview Partners. Garrett received a B.S. from Duke University. He currently serves as a Director of ACP Northern Holdings, EBi Bone Healing, eMolecules, Organogenesis (Nasdaq: ORGO), Taconic Biosciences, and Terrats Medical and previously served as a Director of Solmetex, Spear Education, United BioSource Corporation, and XIFIN.
Elaine Tang: Elaine joined Avista in 2022. Prior to joining Avista, she worked in private equity at Partners Group. Elaine received a B.A. from Wellesley College and an M.B.A. from Harvard Business School. She currently serves as a Director of PK Benelux and Probo Medical.
About Avista Healthcare Partners
Avista Healthcare Partners, founded in 2005 by Thompson Dean and David Burgstahler, is a leading New York-based private equity firm with over
For media inquiries, please contact:
Daniel Yunger / James Lindsay
Kekst CNC
daniel.yunger@kekstcnc.com / james.lindsay@kekstcnc.com
917.574.8582 / 917.842.4119
View original content:https://www.prnewswire.com/news-releases/avista-healthcare-partners-announces-promotions-302652569.html
SOURCE Avista Healthcare Partners
FAQ
Who was promoted at Avista Healthcare Partners on January 5, 2026 (ORGO)?
What backgrounds do the promoted Avista leaders have and how long have they been at the firm?
Does Garrett Lustig serve on the board of any public company such as Organogenesis (ORGO)?
What did Avista's CEO say about the January 5, 2026 promotions?
Where can investors find more information about Avista's leadership and director roles after the promotions?
